Herceptin: from the bench to the clinic.
- 30 January 2001
- journal article
- review article
- Published by Taylor & Francis in Cancer Investigation
- Vol. 19 (1), 49-56
- https://doi.org/10.1081/cnv-100000074
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- c-erbB2 expression predicts tamoxifen efficacy in breast cancer patientsBreast Cancer Research and Treatment, 1998
- Her-2/neu as a Predictive Marker of Response to Breast Cancer TherapyBreast Cancer Research and Treatment, 1998
- Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibodyBreast Cancer Research and Treatment, 1997
- Inhibition of Human Lung Cancer Cell Line Growth by an Anti-p185HER2 AntibodyAmerican Journal of Respiratory Cell and Molecular Biology, 1993
- Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodiesCancer Immunology, Immunotherapy, 1993
- Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neuBreast Cancer Research and Treatment, 1992
- Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinicJournal of Clinical Immunology, 1991
- Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: Neu and tamoxifen failureThe Journal of Steroid Biochemistry and Molecular Biology, 1990
- p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor.Molecular and Cellular Biology, 1989
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987